Your browser doesn't support javascript.
loading
PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
Davern, Maria; O' Brien, Rebecca M; McGrath, Jason; Donlon, Noel E; Melo, Ashanty M; Buckley, Croí E; Sheppard, Andrew D; Reynolds, John V; Lynam-Lennon, Niamh; Maher, Stephen G; Lysaght, Joanne.
Afiliação
  • Davern M; Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.
  • O' Brien RM; Translational Radiobiology and Diagnostics Group, Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.
  • McGrath J; Translational Radiobiology and Diagnostics Group, Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.
  • Donlon NE; Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.
  • Melo AM; Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.
  • Buckley CE; Translational Radiobiology and Diagnostics Group, Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.
  • Sheppard AD; Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.
  • Reynolds JV; Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.
  • Lynam-Lennon N; Translational Radiobiology and Diagnostics Group, Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.
  • Maher SG; Cancer Chemoradiation Group, Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.
  • Lysaght J; Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland. jlysaght@tcd.ie.
Sci Rep ; 12(1): 3259, 2022 02 28.
Article em En | MEDLINE | ID: mdl-35228614
ABSTRACT
Chemotherapy upregulates immune checkpoint (IC) expression on the surface of tumour cells and IC-intrinsic signalling confers a survival advantage against chemotherapy in several cancer-types including oesophageal adenocarcinoma (OAC). However, the signalling pathways mediating chemotherapy-induced IC upregulation and the mechanisms employed by ICs to protect OAC cells against chemotherapy remain unknown. Longitudinal profiling revealed that FLOT-induced IC upregulation on OE33 OAC cells was sustained for up to 3 weeks post-treatment, returning to baseline upon complete tumour cell recovery. Pro-survival MEK signalling mediated FLOT-induced upregulation of PD-L1, TIM-3, LAG-3 and A2aR on OAC cells promoting a more immune-resistant phenotype. Single agent PD-1, PD-L1 and A2aR blockade decreased OAC cell viability, proliferation and mediated apoptosis. Mechanistic insights demonstrated that blockade of the PD-1 axis decreased stem-like marker ALDH and expression of DNA repair genes. Importantly, combining single agent PD-1, PD-L1 and A2aR blockade with FLOT enhanced cytotoxicity in OAC cells. These findings reveal novel mechanistic insights into the immune-independent functions of IC-intrinsic signalling in OAC cells with important clinical implications for boosting the efficacy of the first-line FLOT chemotherapy regimen in OAC in combination with ICB, to not only boost anti-tumour immunity but also to suppress IC-mediated promotion of key hallmarks of cancer that drive tumour progression.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Antígeno B7-H1 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Antígeno B7-H1 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article